Page last updated: 2024-09-05

sb 216763 and Neoplasms

sb 216763 has been researched along with Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Flajolet, M; Greengard, P; Meijer, L1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Alam, MS; Hamid, H; Khan, I; Tantray, MA1
Duan, Y; Han, J; Hou, S; Liao, C; Wang, Q; Xie, Z; Yang, X1
Khuri, FR; Li, S; Oh, YT; Sun, SY; Yue, P1
Aono, Y; Ichikawa, M; Iizumi, Y; Sakai, T; Sowa, Y1

Reviews

3 review(s) available for sb 216763 and Neoplasms

ArticleYear
Pharmacological inhibitors of glycogen synthase kinase 3.
    Trends in pharmacological sciences, 2004, Volume: 25, Issue:9

    Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Neoplasms; Nervous System Diseases; Parasitic Diseases; Signal Transduction; Stem Cells; Structure-Activity Relationship

2004
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    European journal of medicinal chemistry, 2017, Jan-05, Volume: 125

    Topics: Alzheimer Disease; Animals; Bipolar Disorder; Clinical Trials as Topic; Diabetes Mellitus; Drug Discovery; Glycogen Synthase Kinase 3; Humans; Models, Molecular; Neoplasms; Patents as Topic; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction

2017
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
    Journal of medicinal chemistry, 2022, 05-12, Volume: 65, Issue:9

    Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhibitors

2022

Other Studies

3 other study(ies) available for sb 216763 and Neoplasms

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
    Oncogene, 2016, Feb-04, Volume: 35, Issue:5

    Topics: Cell Cycle Proteins; Cell Line, Tumor; Enzyme Inhibitors; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; HCT116 Cells; Humans; Indoles; Lipogenesis; Maleimides; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Neoplasms; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases; Transfection; Ubiquitin-Protein Ligases

2016
Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Annexin A5; Apoptosis; Bufanolides; Cardiotonic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cyclin D1; G1 Phase; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Medicine, Chinese Traditional; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Retinoblastoma Protein

2015